Pharmacy Quality Alliance | Strategic Alliance Partners

PQA is a national quality organization that brings 250 organizations from across health care together to develop and implement quality measures, conduct research and provide education that supports better medication use and high-quality care.

Curriculum’s advanced training offers strategies to approve drug adherence, appropriate use, and safety.

The project aims to demonstrate the value of collaboration between pharmacists and health care payers in the delivery of patient-centered care.

Pharmacy Times® spoke with Laura Cranston, RPh, CEO of Pharmacy Quality Alliance (PQA), about what is next for the organization after the recent announcement that Cranston is stepping down by the end of 2020.

Loren Kirk, director of Stakeholder Engagement for the Pharmacy Quality Alliance, speaks to Pharmacy Times on the findings of the Pharmacy-Provided Care Action Guide Report, during the Pharmacy Quality Alliance Annual Meeting.

Loren Kirk, director of Stakeholder Engagement for the Pharmacy Quality Alliance, speaks to Pharmacy Times on phases of the Pharmacy-Provided Care Action Guide Report, during the Pharmacy Quality Alliance Annual Meeting.

Loren Kirk, director of Stakeholder Engagement for the Pharmacy Quality Alliance (PQA), speaks to Pharmacy Times on the origins and goals of the Pharmacy-Provided Care Action Guide Report, during the PQA Annual Meeting.

In a prepared statement, Pharmacy Quality Alliance (PQA) Chief Executive Officer Laura Cranston, RPh, said the organization applauds the initiatives outlined in “Executive Order on Improving Price and Quality Transparency in American Healthcare to Put Patients First.”

Norris Turner, PharmD, PhD, vice president of Strategic Alliances and Measures at PQA, discusses value-based contracts and the demand for medication measurements in Medicaid during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Matthew Pickering, PharmD, RPh, PQA Senior Director of Research & Quality Strategies at Pharmacy Quality Alliance discusses its medication access framework for quality measurement during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the organization's origins as a measure developer during the PQA Annual Meeting in Baltimore, MD.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and how they complement existing measures during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Norris Turner, PharmD, PhD, vice president of Strategic Alliances and Measures at PQA discusses the uses of PQA's measures in Medicaid during the Pharmacy Quality Alliance Annual Meeting in Baltimore, MD.

Laura Cranston, RpH, CEO of Pharmacy Quality Alliance (PQA), discusses the current landscape of medication quality during the PQA Annual Meeting in Baltimore, MD.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses the alliance's new opioid measures and how PQA identified the need for them during the PQA Annual Meeting in Baltimore, MD.

Lisa Hines, PharmD, vice president of Measurement and Operations at Pharmacy Quality Alliance (PQA), discusses PQA's new opioid measures and what they evaluate during the PQA Annual Meeting in Baltimore, MD.

The Pharmacy Quality Alliance has praised the bipartisan efforts of Congress in passing the SUPPORT for Patients and Communities Act (HR 6).

In this clip, Ben Urick, PharmD, PhD, a research assistant professor at the University of North Carolina Eshelman School of Pharmacy, discusses the value that the Pharmacy Quality Alliance (PQA) brings to the health care system.

At the 12th annual meeting of the Pharmacy Quality Alliance held recently in Baltimore, Maryland, several speakers shared ideas on converting patient input into meaningful performance measures.

The membership of the Pharmacy Quality Alliance has endorsed two new performance measures: Concurrent Use of Opioids and Benzodiazepines and Adherence to Non-Infused Disease Modifying Agents Used to Treat Multiple Sclerosis.